Background and Aims: NSCLC which accounts for 85% cases of lung cancer, have a low rate of 1-year survival especially in developing countries. In Indonesia, there are still limited data on survival of NSCLC patients and reported from various hospital-based study.
Results: There were 75 NSCLC patients, age range 19-76 years, 74.7% men, 58.7% normal BMI, 70.7% smoking and ECOG 3-4, 50.7% CCI score >1, and 62.7% non-adenocarcinoma. The median survival is 135 days and the 1-year survival rate is 13%. Bivariate analysis showed that age 40-49 years (180 days and 19%, P = 0.036), normal BMI (198 days and 20%, P = 0.015), on targeted therapy (240 days and 33%, P = 0,000), ECOG 1-2 (270 days and 32%, P = 0,000), CCI score <1 (218 days and 24%, P = 0,000), and normal albumin (180 days and 13%, P = 0.024). Have significant impact on median and high rate of 1-year survival. Median survival was high in subjects with pleural effusions (180 days), but the likelihood rate was high in subjects without pleural effusion (20%, P = 0.0260). Multivariate analysis showed that performance status and therapy had the most dominant impact on the 1-year survival.
Conclusion: 1-year survival rate of NSCLC patients in Dr. Wahidin Sudirohusodo hospital is 13% and influenced mainly by the performance status and therapy. Background and Aims: Small cell lung cancer (SCLC) is more effective against chemotherapy and radiotherapy than lung cancer of other cell types. On the other hand, FN is an adverse event caused by treatment with anticancer drugs and is often fatal. We examined the relationship between SCLC and FN this time.
Methods: This subject was a patient diagnosed with SCLC and treated with anticancer drug on April 1, 2013 to March 31, 2017. We compared FN cases with those who did not develop FN during treatment of the first regimen. This study is a retrospective study and data was collected from medical records. Differences between responders and nonresponders were screened by the Mann-Whitney U test. Prognosis was studied over the entire survival period.
Results: We examined this case in 20 patients who developed FN in the first regimen. 35 cases did not develop. The median age was 71.5, the median MASCC score was 19.5 points, and the low risk group was 12 cases of FN patients who developed on the first regimen. In FN onset cases and in non -onset cases with FN, radiation therapy combined was 3 cases and 3 cases respectively. There was no significant difference between the LD and 6 cases and 10 cases respectively. ade highlights the importance of tumor microenvironment (TME) and host immune systems. PD-L1 can be upregulated in hypoxic or acidic TME. PINK1 is a mitochondrial serine/threonine kinase that has ambiguous roles in cancer. PINK1 loss of function reduces mitochondrial OXPHOS and reshapes tumor cells into a glycolytic phenotype. These suggest the role of PINK1 in TME and PD-L1 regulation. In the current study, we aim to investigate whether PINK1 regulates PD-L1 and its potential role in lung cancer immunotherapy.
Methods: As the expression of PD-L1 can be influenced by the tumor cell itself and the surrounding TME, we first investigated whether PINK1 affects PD-L1 expression in four lung cancer cell lines, CL1-0, CL1-5, A549 and EKVX. Cells were transfected with siPINK1 or PINK1 plasmid for PINK1 manipulation. Changes of metabolic phenotypes upon PINK1 manipulation were investigated by Seahorse XF96 Analyzer. Changes of PD-L1 expressions were examined by RT-qPCR and immunoblots. Related mechanisms were explored by immunoprecipitation and immunoblots.
Results:
The results showed that PINK1 knockdown upregulated PD-L1 transcription and translation in CL1-5 and EKVX cells, but not CL1-0 or A549 cells. When compared with A549 cells, CL1-5 cells were assigned to be of glycolytic phenotype and the degree of glycolysisdependency increased with PINK1 knockdown. The change of MHC-I expression was in concordance with that of PD-L1 upon PINK1 manipulation. We also showed that the regulation was mediated in part by STAT family proteins or HIF-1α, dependent on different cellular contexts.
Conclusion: PINK1 regulates PD-L1 and MHC-I expression in lung cancer with glycolytic phenotype. As MHC-I and PD-L1 play pivotal roles in cancer immunotherapy, our discovery facilitates therapeutic development not only for TME reshaping but also for immune escape modulation. Background and Aims: Lung cancer is the second leading cause of cancer-specific death among women in Indonesia and the incidence increases continuously from year to year. The main cause of lung cancer is smoking, but it is unlikely occurred in women, especially in Asia and Indonesia. Lung cancer is caused by multifactor, and about 10-15% of lung cancer in the world are found in non-smokers. This study aims to
